Key Points
- Insider sale: EVP Shannon Parisotto sold 2,156 Charles River Laboratories shares for approximately $742,548 under a pre-arranged Rule 10b5-1 trading plan, reducing her ownership by 30.96% to 4,807 shares.
- Quarterly results: Charles River reported quarterly EPS of $3.02, beating estimates of $2.77, while revenue reached $1 billion but declined 2.7% year over year. The company issued fiscal 2026 EPS guidance of $11.15 to $11.45.
- Analyst outlook: The stock has a consensus “Moderate Buy” rating, with an average price target of $302.33; shares recently opened at $345.08, near their 12-month high of $351.21.
Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) EVP Shannon Parisotto sold 2,156 shares of the firm's stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total transaction of $742,547.96. Following the completion of the transaction, the executive vice president owned 4,807 shares in the company, valued at $1,655,578.87. The trade was a 30.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Charles River Laboratories International Stock Performance
Shares of NYSE CRL opened at $345.08 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The business's 50 day moving average is $294.35 and its two-hundred day moving average is $233.22. The company has a market cap of $16.47 billion, a P/E ratio of -71.15, a P/E/G ratio of 3.17 and a beta of 1.40. Charles River Laboratories International, Inc. has a 12 month low of $146.20 and a 12 month high of $351.21.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. During the same period in the prior year, the business earned $3.12 earnings per share. Charles River Laboratories International's revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current year.
Analyst Upgrades and Downgrades
Several brokerages recently commented on CRL. Morgan Stanley boosted their price target on Charles River Laboratories International from $300.00 to $340.00 and gave the company an "overweight" rating in a research note on Monday, October 12th. TD Cowen upped their target price on shares of Charles River Laboratories International from $300.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, September 25th. UBS Group assumed coverage on shares of Charles River Laboratories International in a research note on Wednesday, September 30th. They set a "buy" rating and a $357.00 price target on the stock. Robert W. Baird raised their price target on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the company an "outperform" rating in a report on Friday, September 25th. Finally, BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $302.33.
View Our Latest Report on CRL
Institutional Investors Weigh In On Charles River Laboratories International
A number of institutional investors and hedge funds have recently modified their holdings of the business. Physician Wealth Advisors Inc. boosted its stake in Charles River Laboratories International by 127.9% in the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company's stock valued at $29,000 after acquiring an additional 55 shares during the last quarter. Continuum Advisory LLC acquired a new stake in Charles River Laboratories International during the 2nd quarter worth $30,000. IFP Advisors Inc raised its position in shares of Charles River Laboratories International by 182.8% during the 3rd quarter. IFP Advisors Inc now owns 164 shares of the medical research company's stock valued at $48,000 after acquiring an additional 106 shares during the last quarter. Compass Wealth Management LLC bought a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $69,000. Finally, Activest Wealth Management lifted its stake in shares of Charles River Laboratories International by 25.9% in the 3rd quarter. Activest Wealth Management now owns 277 shares of the medical research company's stock valued at $82,000 after purchasing an additional 57 shares during the period. 98.91% of the stock is owned by institutional investors.
Charles River Laboratories International Company Profile
(
Get Free Report)
Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.
Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
